Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Sorter
Keyphrases
All-cause Mortality
25%
Assessment Development
8%
Assessment Evaluation
8%
Atrial Fibrillation
8%
Atrial Fibrillation Risk
8%
Beneficial Effects
8%
Bradycardia
16%
Cardiac Failure
8%
Cardiovascular Mortality
25%
Certainty of Evidence
41%
Control Risk
8%
Database Registries
8%
Embase
8%
Event Risk
8%
Failure Risk
8%
Grading of Recommendations
8%
Harmful Effects
8%
Heart Failure
16%
High Risk
8%
Hospitalization
8%
Hospitalization Risk
8%
Ivabradine
100%
Kansas City Cardiomyopathy Questionnaire
16%
Low Risk
8%
MEDLINE
8%
Meta-analysis
100%
Minnesota Living with Heart Failure Questionnaire (MLHFQ)
16%
Myocardial Infarction
25%
Non-serious
25%
Number Needed to Harm
16%
Number-needed-to-treat
33%
Patients with Heart Failure
100%
Placebo
8%
Prospero
8%
Quality of Life
25%
Random Error
8%
Randomized Clinical Trial
16%
Registration number
8%
Risk of Bias
16%
Risk of Bias Tool
8%
Risk Ratio
58%
Serious Adverse Events
50%
Systematic Error
8%
Trial Registries
8%
Trial Sequential Analysis
100%
Usual Care
100%
Ventricular Tachycardia
8%
Nursing and Health Professions
Adverse Event
50%
All Cause Mortality
25%
Atrial Fibrillation
16%
Bradycardia
16%
Cardiovascular Mortality
25%
Clinical Trial
16%
Congestive Heart Failure
100%
Effect Size
8%
Embase
8%
Heart Infarction
25%
Heart Ventricle Tachycardia
8%
Ivabradine
100%
Medline
8%
Meta Analysis
41%
Myocardial Disease
16%
Number Needed to Harm
16%
Numbers Needed to Treat
33%
Placebo
8%
Quality of Life
25%
Random Error
8%
Sequential Analysis
100%
Systematic Error
8%
Systematic Review with Meta-Analysis
100%
Vasoactive Intestinal Polypeptide
8%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
50%
All Cause Mortality
25%
Atrial Fibrillation
16%
Bradycardia
16%
Cardiovascular Mortality
25%
Congestive Heart Failure
100%
Heart Infarction
25%
Heart Ventricle Tachycardia
8%
Ivabradine
100%
Myocardial Disease
16%
Number Needed to Harm
16%
Number Needed to Treat
33%
Placebo
8%
Randomized Clinical Trial
16%
Vasoactive Intestinal Polypeptide
8%